📰 Endogenous Cannabinoids News
Endogenous Cannabinoids News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Endogenous Cannabinoids. Real-time updates on events, politics, business and more.
January 19, 2022
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
January 19, 2022
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
January 19, 2021
VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe ("CDP Europe"). CDP Europe will be held virtually from January 19-21,...